Debbie Rigby rounds up the latest in research news
Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. It develops in a dose and time dependent manner, due to a rapid and transient increase in bone resorption, followed by the inhibition of bone formation. While oral bisphosphonates remain the most used and cost-effective option, more potent antiresorptive agents (e.g. denosumab and zoledronate) or anabolic compounds (e.g. teriparatide) lead to higher BMD increases.
Expert Opinion on Pharmacotherapy, published online 31 Jan 2020.
Approximately 20% of patients with obstructive lung disease have features of both asthma and chronic obstructive pulmonary disease. As inhaled corticosteroids are key to the management of asthma, they are recommended in patients with overlapping chronic obstructive pulmonary disease. Smoking cessation, vaccination, inhaler technique assessment, written action plan and bronchodilators for symptom control are other important interventions.
Aust Prescr 2020;43:7–11.
Treatment of heart failure with preserved ejection fraction (HFpEF) or diastolic dysfunction should be tailored to the individual’s associated comorbidities. Common comorbidities include coronary artery disease, atrial fibrillation, obesity, diabetes, renal impairment and pulmonary hypertension. Key treatment objectives include control of hypertension and fluid balance.
Aust Prescr 2020;43:12–7.
A live, attenuated single-dose vaccine, that protects against both acute herpes zoster and postherpetic neuralgia, is available for free to all Australians aged 70 years, and in a catch-up program for those aged 71–79 years. Only a third of 70 year olds received the vaccine in the first year-and-a-half of the program. People aged 50–69 years and over 80 years who wish to receive the vaccine have to obtain a prescription and pay for it.
Aust Prescr 2020;43:2–6.